• OrthoPediatrics director David R. Pelizzon sold 22,500 common shares on Sep. 2 at a weighted average price of $23.35.
• Indirect holdings reported at 6,504,133 shares following the transaction.
• Directly held shares reported at 44,384 following the filing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OrthoPediatrics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001425450-26-000085), on September 04, 2026, and is solely responsible for the information contained therein.